Results 161 to 170 of about 5,337 (191)
Some of the next articles are maybe not open access.
Aducanumab, amyloid, and culture wars
BMJ, 2021Those who thought that the US Food and Drug Administration (FDA) was a conservative regulator which maintained a high bar have been shocked by its approval of the anti-amyloid antibody aducanumab. There is precedent. Former president Donald Trump championed hydroxychloroquine as a preventative against covid-19.
Iliffe, Steve, Manthorpe, Jill
openaire +3 more sources
Aducanumab: The first targeted Alzheimer's therapy
Drug Discoveries and Therapeutics, 2021 Alzheimer's disease (AD) is an irreversible brain disorder associated with severe progressive dementia and is characterized by deposits of amyloid plaques in the brain. Over the past 20 years, the mortality of strokes and heart disease has decreased, but deaths from AD have increased. The four drugs used clinically to treat AD can only relieve symptoms
Pan Yang, Fusheng Sun
exaly +4 more sources
, 2021 Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's ...
Kunal Dhiman +2 more
exaly +1 more source
Aducanumab and the FDA — where are we now?
Nature Reviews Neurology, 2021The amyloid antibody aducanumab is currently undergoing review by the FDA. The treatment would be the first disease-modifying drug to be approved for Alzheimer disease; however, a medical advisory committee recently convened by the FDA did not recommend approval, raising questions about whether the existing evidence of efficacy is sufficient.
Howard Fillit, Allan Green
openaire +2 more sources
Aducanumab for Alzheimer’s disease: Observations and opportunities
Australasian Psychiatry, 2022Objective To analyse the overseas approval of aducanumab for Alzheimer’s disease, in order to derive lessons of potential interest to individuals and groups involved in dementia drug development and regulation in Australia. Conclusions
openaire +2 more sources